Profile: Emergent BioSolutions Inc (EBS)
26 May 2015
Emergent BioSolutions Inc., incorporated on December 19, 1998, is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense division and BioSciences division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD.
The Company’s BioDefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or bio-warfare and targets the infectious disease, anthrax. Its programs include a pipeline of investigational product candidates and one marketed product, BioThrax (Anthrax Vaccine Adsorbed), a vaccine approved by the United States Food and Drug Administration (FDA), for the prevention of anthrax disease. Operations in this division include manufacturing, regulatory affairs, quality assurance, quality control, international sales and marketing, and domestic government affairs in support of its marketed products, as well as product development and manufacturing infrastructure in support of its investigational stage product candidates. The Company’s products include BioThrax, pre-exposure prophylaxis of anthrax disease; BAT, treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F or G; AIGIV, treatment of toxemia associated with inhalational anthrax; RSDL for removal and/or neutralization of chemical warfare agents and T-2 toxin from the skin, and VIGIV, post-exposure prophylaxis of vaccinia (a common virus used to vaccinate against small pox
The Company’s Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company’s products include WinRho SDF, a mixture of purified polyclonal human immune globulins (antibodies) directed to Rho(D)(+) red blood cells; HepaGam B, a mixture of purified polyclonal human immune globulins (antibodies) that are directed to the hepatitis B surface antigen; VARIZIG, a mixture of purified polyclonal human immune globulins (antibodies) directed to the Varicella zoster virus, the disease agent that causes chickenpox and shingles, and Episil, a medical device for local management of pain associated with oral mucositis (OM).
The Company competes with CSL Behring, Amgen Inc., GlaxoSmithKline plc, Biotest Pharmaceuticals Corporation, Grifols USA, LLC, Genentech, Inc., Cephalon, Genmab A/S, Pharmacyclics, Inc., Johnson and Johnson, Genentech USA, Inc., Boehringer Ingelheim GmbH, ImmunoGen, Inc., Gilead Sciences, Inc., AbbVie Inc., Pfizer Inc., Baxter International Inc., Biogen Idec Inc., OSO BioPharmaceuticals Manufacturing, LLC, JHP Pharmaceuticals, LLC, Jubilant Hollister-Stier Laboratories LLC, Patheon Inc., Hospira Inc., Ajinomoto Althea, Inc, Cook Pharmica LLC and Albany Molecular Research, Inc.
Emergent BioSolutions Inc
400 Professional Dr Ste 400
GAITHERSBURG MD 20879-3457
Company Web Links
- BRIEF-Evolva Holding completes transfer of EV-035 to Emergent BioSolutions
- FDA approves Emergent BioSolutions' inhaled anthrax treatment
- UPDATE 3-FDA approves Emergent BioSolutions' inhaled anthrax treatment
- FDA approves Emergent BioSolutions' anthrax treatment
- BRIEF-Morphosys initiates phase 1 study with drug to treat prostate cancer